Literature DB >> 1930316

Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results.

J McLaughlin1, D D Gladman, M B Urowitz, C Bombardier, V T Farewell, E Cole.   

Abstract

Renal biopsy specimens from 123 patients with systemic lupus erythematosus (SLE) seen between 1970 and 1984 were assessed according to the World Health Organization classification and according to the presence of proliferative, active, or chronic renal lesions. Survival analysis was used to study the determinants of mortality. Survival rates were higher for patients with minimal lesions, intermediate for patients with focal or diffuse proliferative nephritis, and low for patients with glomerular sclerosis. The presence of proliferative and chronic lesions was associated with a higher risk of dying. Renal biopsy results are helpful in predicting prognosis for all-cause mortality in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1930316     DOI: 10.1002/art.1780341010

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone.

Authors:  P Oelzner; K Abendroth; G Hein; G Stein
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 2.  Prognosis in systemic lupus erythematosus.

Authors:  J M Esdaile
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Drug combination therapy of systemic lupus erythematosus.

Authors:  P A Miescher; H Favre; R Lemoine; Y P Huang
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  Systemic lupus erythematosus--disease management.

Authors:  M F Gourley
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus.

Authors:  A I Villa-Manzano; J I Gamez-Nava; M Salazar-Paramo; I C Valera-Gonzalez; A Garcia-Gonzalez; G Garcia-Gonzalez; J Morales-Romero; A Lopez-Olivo; L M Galvan-Ramirez; R Ruiz-Ruvalcaba; E G Cardona-Muñoz; L Gonzalez-Lopez
Journal:  Rheumatol Int       Date:  2005-10-18       Impact factor: 2.631

Review 6.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients.

Authors:  S Buján; J Ordi-Ros; J Paredes; M Mauri; L Matas; J Cortés; M Vilardell
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.